On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Rohto to Roll Out 3- or 4-Day Workweek Option from April to Spur Growth, Retention
January 15, 2026
-
ORGANIZATION Pharma FTC Clarifies “Simple Beverages” under New Food Rules
January 14, 2026
-
REGULATORY Japan Panel to Review AbbVie’s Aquipta, Ipsen’s Sohonos on January 23
January 13, 2026
-
REGULATORY MHLW Pharma Director Says Uniform Drug Price Hike “Not Realistic,” Targeted Support Preferred
January 9, 2026
-
BUSINESS Bayer/Santen to Launch Eylea Bio-AG on February 2
January 9, 2026
-
BUSINESS Pharma Leaders Press for Drug Pricing Overhaul at New Year’s Confab
January 8, 2026
-
BUSINESS Generic Entry into DPP-4 Class Poised to Accelerate in 2026
January 7, 2026
-
COMMENTARY Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026
January 6, 2026
-
ORGANIZATION FY2026 Reform Tilted toward Price Cuts despite Spillover Scrap: FPMAJ Chair
January 6, 2026
-
ORGANIZATION Pfizer Japan President Igarashi Takes Helm as PhRMA Japan Chair
January 6, 2026
-
ORGANIZATION Industry Leaders Call for Proper Rewards for Innovation in New Year Messages
January 5, 2026
-
REGULATORY Gist of FY2026 Drug Pricing Reform Outline
December 26, 2025
-
REGULATORY Japan Puts CEA Expansion on Hold, Sets 6-Month “Technical Discussions”
December 26, 2025
-
REGULATORY Chuikyo OKs FY2026 Drug Pricing Reform Outline, Scraps “Spillovers” but Adds New Follow-Up Rules
December 26, 2025
-
REGULATORY MHLW Names 77 Active Ingredients for OTC-Like Drug Charges
December 26, 2025
-
REGULATORY Japan Ministers Agree to Scrap “Spillover” Rule, Plan Wider CEA Price Cuts
December 25, 2025
-
REGULATORY Japan Weighs Scrapping “Spillover” Rule in Shift from Draft Reform Outline
December 24, 2025
-
BUSINESS Cyto-Facto Expands CPC Footprint to Win Multiple Cell Therapy Contracts
December 24, 2025
-
REGULATORY Japan Approves Batch of New Drugs, Subcutaneous Rybrevant Finally Cleared
December 23, 2025
-
TRENDS Top 10 PHARMA JAPAN Articles of 2025
December 23, 2025
ページ
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…